Understanding the genomic profiling of prostate cancer is crucial, owing to the emergence of
precision medicine to guide therapeutic approaches. Over the last decade, integrative …

Simple Summary Liquid biopsy (LB), encompassing the analysis of circulating tumor
material in the blood or urine, has emerged as a powerful tool in the management of …

We evaluated the advantages and the reliability of novel protocols for the enrichment of
tumor extracellular vesicles (EVs), enabling a blood-based test for the noninvasive parallel …

Background. EPI-506 is the first of a new class of drugs targeting the N-terminal domain
(NTD) of the androgen receptor (AR), potentially overcoming known resistance mechanisms …

Abstract Background The phase 3 CALGB 90203 (Alliance) trial evaluated neoadjuvant
chemohormonal therapy for high-risk localized prostate cancer before radical prostatectomy …

Prostate cancer remains the second‐most common cancer diagnosed in men, despite the
increasingly widespread use of serum prostate‐specific antigen (PSA) screening. The …

In the past decade, a revolution in the treatment of metastatic prostate cancer has occurred
with the advent of novel hormonal agents and life-prolonging chemotherapy regimens in …

Given the low specificity of the routinely used biomarker prostate-specific antigen, circulating
tumor cell (CTC) enumeration seems to be particularly useful in the monitoring of prostate …

Clinical genomic testing is becoming routine in prostate cancer, as biomarker‐driven
therapies such as poly‐ADP ribose polymerase (PARP) inhibitors and anti‐PD1 …

PURPOSE Androgen receptor (AR) gene alterations, including ligand-binding domain
mutations and copy number (CN) gain, have yet to be fully established as predictive markers …